ALKS - Alkermes plc
| Previous Close | 44.45 |
| Open | 44.11 |
| Bid | 0.00 x 900 |
| Ask | 0.00 x 1000 |
| Day's Range | 43.58 - 44.43 |
| 52 Week Range | 39.54 - 71.22 |
| Volume | 223,228 |
| Avg. Volume | 684,706 |
| Market Cap | 6.796B |
| Beta | 2.57 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.99 |
| Earnings Date | Oct 24, 2018 - Oct 29, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 52.38 |
Market Realist•15 hours agoWhat Does Nektar Therapeutics’ Valuation Trend Indicate?
Under its immunology program, Nektar Therapeutics (NKTR) is developing NKTR-358 in collaboration with Eli Lilly and Company (LLY).
Market Realist•yesterdayAnalysts Remain Bullish on Nektar Stock in August
Nektar Therapeutics (NKTR), a research-focused biopharmaceutical company, is developing a strong pipeline of product candidates that make use of its polymer conjugate technology platforms. This pipeline includes investigational drugs for the treatment of cancer, autoimmune disease, and chronic pain.
Markit•8 days agoSee what the IHS Markit Score report has to say about Alkermes PLC.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
- American City Business Journals•8 days ago
Alkermes settles gender bias lawsuits for undisclosed amounts
Alkermes opted to settle the two complaints before they reached trial for undisclosed sums, with at least one including a confidentiality agreement.
- Zacks•9 days ago
ANIK vs. ALKS: Which Stock Is the Better Value Option?
ANIK vs. ALKS: Which Stock Is the Better Value Option?
Markit•14 days agoSee what the IHS Markit Score report has to say about Alkermes PLC.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
- PR Newswire•14 days ago
Alkermes' Corporate Presentation to be Webcast at the 38th Annual Canaccord Genuity Growth Conference
DUBLIN , Aug. 1, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the 38 th Annual Canaccord Genuity Growth Conference on Wednesday, ...
- Motley Fool•20 days ago
Collaborations Help Alkermes Flip to Profitability
The commercial-stage biopharma posts revenue growth of 39% thanks to increased product sales and a sizeable milestone payment.
- Thomson Reuters StreetEvents•20 days ago
Edited Transcript of ALKS earnings conference call or presentation 26-Jul-18 12:30pm GMT
Q2 2018 Alkermes Plc Earnings Call
- Associated Press•21 days ago
Alkermes: 2Q Earnings Snapshot
The Dublin-based company said it had a loss of 21 cents per share. Earnings, adjusted for stock option expense and non-recurring costs, came to 29 cents per share. The results topped Wall Street expectations. ...
Markit•21 days agoSee what the IHS Markit Score report has to say about Alkermes PLC.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
- PR Newswire•21 days ago
Alkermes Plc Reports Second Quarter 2018 Financial Results
-- Second Quarter Revenues Increase to $304.6 Million , Driven by License Revenues and 24% Year-Over-Year Growth of Proprietary Product Net Sales -- -- Company Reports GAAP Net Loss per Share of $0.21 ...
- Benzinga•21 days ago
Earnings Preview: Alkermes
Don't be caught off-guard: Alkermes (NASDAQ: ALKS ) releases its next round of earnings this Thursday. Want to skip the homework and get all the facts in one place? We thought so. Here is your everything-that-matters ...
Markit•26 days agoSee what the IHS Markit Score report has to say about Alkermes PLC.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
- PR Newswire•27 days ago
Alkermes to Host Conference Call to Discuss Second Quarter 2018 Financial Results
DUBLIN , July 19, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:30 a.m. ET ( 1:30 p.m. BST ) on Thursday, July 26, 2018 , to discuss the company's ...
Market Realist•last monthWhy Wall Street Analysts Are Mostly Positive on Alkermes
Today, Alkermes (ALKS) is trading at a stock price of $42.29, which represents ~2.62% growth from its prior close of $41.21 on July 5.
- Benzinga•last month
A Look At Biotech In 2018 And The Biggest Catalysts Coming Up In The Second Half Of The Year
Biotech stocks carved out modest gains in the first half of 2018 and outperformed the broader market, although their gains paled before those of the tech-weighted Nasdaq Composite Index. From the fundamental ...
- Zacks•last month
Alkermes' Aristada Initio Approved by FDA for Schizophrenia
FDA approves Alkermes' (ALKS) Aristada Initio (aripiprazole lauroxil) for the treatment of schizophrenia in adults.
- Benzinga•last month
Benzinga Pro's 5 Stocks To Watch Today
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Alkermes Plc (NASDAQ: ALKS ) stock was trading higher ...
- PR Newswire•last month
FDA Approves ARISTADA INITIO™ for the Initiation of ARISTADA® for Schizophrenia
DUBLIN, July 2, 2018 /PRNewswire/ -- Alkermes plc (ALKS) today announced that the U.S. Food and Drug Administration (FDA) has approved ARISTADA INITIO™ (aripiprazole lauroxil) for the initiation of ARISTADA® (aripiprazole lauroxil), a long-acting injectable atypical antipsychotic for the treatment of schizophrenia in adults. For the first time, ARISTADA INITIO, in combination with a single 30 mg dose of oral aripiprazole, provides physicians with an alternative regimen to initiate patients onto any dose of ARISTADA on day one. ARISTADA INITIO is expected to be available in mid-July.
- Benzinga•2 months ago
The Week Ahead In Biotech: Conferences, Clinical Trials And IPOs
Biotech stocks saw some upward momentum last week. The defensive nature of biotech stocks drove investors into the space amid a rise in risk aversion following the ongoing U.S.-China trade war. The week ...
- Motley Fool•2 months ago
Why Alkermes Tumbled 15% Today
A downgrade by a big investment bank took a toll on the company's shares today.
- Motley Fool•2 months ago
Why Stamps.com, iQiyi, and Alkermes Slumped Today
Find out which of these companies could suffer from a government move.
- MarketWatch•2 months ago
Drugs from Heron Therapeutics and two other biotech companies can boost your investment returns by reducing opioid abuse
Heron Therapeutics, Cara Therapeutics and Alkermes are discovering novel replacements for dangerous opioidsAbout 2.1 million people in the U.S. suffer from opioid abuse. While investors are focused on trade wars as a potential threat to their wealth, drug abuse may be the bigger risk. Fortunately, three biotech companies are coming to the rescue, which makes them good investments.
